Cytosorbents Corp (CTSO) stock
CTSONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 19, 2026Score 2/30
$5.57+1.05 (+23.12%)
Close on Nov 18, 2026Market cap $349.72MP/E –Yield –
Cytosorbents revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Cytosorbents's revenue for the twelve months ending Sep 30, 2026 was $37.46M, up 1.3% year over year. For fiscal 2025 it was $37.06M, up 4.1% from the year before. Over ten years it grew 22.7% a year on average. The highest annual figure on record is $43.17M in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $37.06M | +4.1% |
| FY2024 | Dec 31, 2024 | $35.60M | +14.5% |
| FY2023 | Dec 31, 2023 | $31.08M | -10.4% |
| FY2022 | Dec 31, 2022 | $34.69M | -19.6% |
| FY2021 | Dec 31, 2021 | $43.17M | +5.3% |
| FY2020 | Dec 31, 2020 | $41.00M | +64.4% |
| FY2019 | Dec 31, 2019 | $24.95M | +10.9% |
| FY2018 | Dec 31, 2018 | $22.50M | +48.5% |
| FY2017 | Dec 31, 2017 | $15.15M | +59.0% |
| FY2016 | Dec 31, 2016 | $9.53M | +98.8% |
| FY2015 | Dec 31, 2015 | $4.79M | +16.2% |
| FY2014 | Dec 31, 2014 | $4.12M | +70.2% |
| FY2013 | Dec 31, 2013 | $2.42M | +80.4% |
| FY2012 | Dec 31, 2012 | $1.34M | +3622.3% |
| FY2011 | Dec 31, 2011 | $36.08K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $9.73M | +2.6% |
| Q2 FY2026 | Jun 30, 2026 | $9.63M | +0.2% |
| Q1 FY2026 | Mar 31, 2026 | $8.86M | +1.6% |
| Q4 FY2025 | Dec 31, 2025 | $9.23M | +0.9% |
| Q3 FY2025 | Sep 30, 2025 | $9.49M | +10.1% |
| Q2 FY2025 | Jun 30, 2025 | $9.62M | +8.8% |
| Q1 FY2025 | Mar 31, 2025 | $8.73M | -2.9% |
| Q4 FY2024 | Dec 31, 2024 | $9.15M | +5.6% |
| Q3 FY2024 | Sep 30, 2024 | $8.61M | -2.2% |
| Q2 FY2024 | Jun 30, 2024 | $8.84M | -6.1% |
| Q1 FY2024 | Mar 31, 2024 | $8.99M | -4.9% |
| Q4 FY2023 | Dec 31, 2023 | $8.67M | -7.7% |
| Q3 FY2023 | Sep 30, 2023 | $8.81M | +8.6% |
| Q2 FY2023 | Jun 30, 2023 | $9.42M | +10.9% |
| Q1 FY2023 | Mar 31, 2023 | $9.45M | +8.7% |
| Q4 FY2022 | Dec 31, 2022 | $9.39M | -12.9% |
| Q3 FY2022 | Sep 30, 2022 | $8.11M | -16.9% |
| Q2 FY2022 | Jun 30, 2022 | $8.50M | -29.3% |
| Q1 FY2022 | Mar 31, 2022 | $8.69M | -18.0% |
| Q4 FY2021 | Dec 31, 2021 | $10.78M | -9.8% |
| Q3 FY2021 | Sep 30, 2021 | $9.76M | -7.5% |
| Q2 FY2021 | Jun 30, 2021 | $12.02M | +22.8% |
| Q1 FY2021 | Mar 31, 2021 | $10.60M | +21.7% |
| Q4 FY2020 | Dec 31, 2020 | $11.96M | +60.9% |
| Q3 FY2020 | Sep 30, 2020 | $10.55M | +73.0% |
| Q2 FY2020 | Jun 30, 2020 | $9.79M | +57.2% |
| Q1 FY2020 | Mar 31, 2020 | $8.71M | +67.7% |
| Q4 FY2019 | Dec 31, 2019 | $7.43M | +22.2% |
| Q3 FY2019 | Sep 30, 2019 | $6.10M | +6.1% |
| Q2 FY2019 | Jun 30, 2019 | $6.23M | +8.3% |
| Q1 FY2019 | Mar 31, 2019 | $5.19M | +5.4% |
| Q4 FY2018 | Dec 31, 2018 | $6.08M | +30.9% |
| Q3 FY2018 | Sep 30, 2018 | $5.74M | +50.2% |
| Q2 FY2018 | Jun 30, 2018 | $5.76M | +61.4% |
| Q1 FY2018 | Mar 31, 2018 | $4.92M | +58.2% |
| Q4 FY2017 | Dec 31, 2017 | $4.65M | +50.7% |
| Q3 FY2017 | Sep 30, 2017 | $3.82M | – |
| Q2 FY2017 | Jun 30, 2017 | $3.57M | – |
| Q1 FY2017 | Mar 31, 2017 | $3.11M | – |
| Q4 FY2016 | Dec 31, 2016 | $3.08M | – |
See a number that looks wrong?